| 查看: 1239 | 回复: 5 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[求助]
求两段翻译，非常紧急，感激涕零
|
|||
|
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80–1.25 。 Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated. A can be co-administered with B、C、Dwithout dose adjustment of either drug |
回复此楼» 猜你喜欢
0857调剂
已经有3人回复
-
材料学调剂
已经有11人回复
-
材料类求调剂
已经有11人回复
-
高分子化学与物理调剂
已经有11人回复
-
26申博
已经有6人回复
-
328求调剂
已经有5人回复
-
化工专硕348，一志愿985求调剂
已经有8人回复
-
0856求调剂285
已经有8人回复
-
290求调剂
已经有11人回复
-
281求调剂
已经有7人回复
Mally89
铁杆木虫 (职业作家)
T_T
- 翻译EPI: 79
- 应助: 7 (幼儿园)
- 贵宾: 1.257
- 金币: 5347.3
- 散金: 8936
- 红花: 49
- 帖子: 3712
- 在线: 1225.5小时
- 虫号: 1150928
- 注册: 2010-11-19
- 性别: MM
- 专业: 肿瘤免疫
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
sltmac(金币+41, 翻译EPI+1): 2011-05-16 07:52:15
sltmac: 继续努力~~ 2011-05-16 07:52:30
sltmac(金币+41, 翻译EPI+1): 2011-05-16 07:52:15
sltmac: 继续努力~~ 2011-05-16 07:52:30
|
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A。 在进行持续三个周期，随机开放标记的三个处理交叉治疗研究当中，10个样本中加入10mg的A，45mg的B或者二者的混合物，另外20个样本中加入20mg的A、1000mg的C或者二者的混合物。在另一个随机开放标记，维持5个周期的5个交叉不平衡处理研究当中，首先向12个样本中加入20mg A，4mg D或者二者混合物，然后再加入100mg西他列汀或加有20mgA的西他列汀。 |
5楼2011-05-08 15:22:48
Mally89
铁杆木虫 (职业作家)
T_T
- 翻译EPI: 79
- 应助: 7 (幼儿园)
- 贵宾: 1.257
- 金币: 5347.3
- 散金: 8936
- 红花: 49
- 帖子: 3712
- 在线: 1225.5小时
- 虫号: 1150928
- 注册: 2010-11-19
- 性别: MM
- 专业: 肿瘤免疫
【答案】应助回帖
|
Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80–1.25 。 每个处理周期72小时之后将血液样本取出。根据几何方法和混合物90%置信区间（在0.8-1.25范围内的单一治疗）的比值来判定交叉反应中是否缺乏PK。 |
6楼2011-05-08 16:09:08
10